Dental treatment with Chitra-CPC and Mineral Trioxide Aggregate materials and compare the results using X-Rays and clinical examination

Efficacy of Chitra-CPC compared to mineral trioxide aggregate as pulpotomy agents in deciduous teeth - A randomised clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2011/04/001663

Enrollment

Registered

2011-04-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Grossly decayed deciduous lower molar teeth indicated for pulpotamy in dental treatment (dentistry)

Interventions

Intervention1: Chitra-CPC: 0.1g of Chitra-CPC (Calcium Phospate Cement) will applied once. (Chitra-CPC is a product developed by Sree Chitra Thirunal Institute for Medical Sciences and Technology, Thi

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients in good general health and free of any systemic disease including congenital heart disease, bleeding disorders etc. 2. Patients who come in the Frankel?s Behaviour Rating Scale No 2, 3, 4. 3. Patients willing for at least 12 months follow up. 4. Teeth that could be restored with stainless steel crown.

Exclusion criteria

Exclusion criteria: 1. Patients in the Frankel?s Behaviour Rating Scale No 1. 2. Parent not willing to take part in the study. 3. Teeth that could not be isolated using rubber dam. 4. Teeth requiring dental treatment other than pulpotomy. 5. Teeth with clinical symptoms or evidence of pulp degeneration, such as pain on percussion, history of swelling, or sinus tracts. 6. Teeth with radiographic signs of internal or external resorption and furcation radiolucency.

Design outcomes

Primary

Measure	Time frame
After treating the teeth using Chitra-CPC with regenerative potential, there will be active dentinal bridge formation and the tooth will be asymptomatic in the future. The patient will be clinically evaluated with, 1. No pain on percussion. 2. No abscess or sinus formation. 3. No pathological tooth mobility. 4. No signs of gingival inflammation.Timepoint: 1) Clinical evaluation - 1st, 3rd, 6th & 12th month 2) Radiographic evaluation - 3rd, 6th & 12th month	—

Measure

Time frame

After treating the teeth using Chitra-CPC with regenerative potential, there will be active dentinal bridge formation and the tooth will be asymptomatic in the future. The patient will be clinically evaluated with, 1. No pain on percussion. 2. No abscess or sinus formation. 3. No pathological tooth mobility. 4. No signs of gingival inflammation.Timepoint: 1) Clinical evaluation - 1st, 3rd, 6th & 12th month 2) Radiographic evaluation - 3rd, 6th & 12th month

—

Secondary

Measure	Time frame
Usage of pulpotomy agent developed indigenously in India (Sree Chitra Thirunal Institute for Medical Sciences and Technology, Thiruvananthapuram)for use in dentistryTimepoint: 1) Clinical evaluation - 1st, 3rd, 6th & 12th month 2) Radiographic evaluation - 3rd, 6th & 12th month	—

Countries

India

Contacts

Public ContactDr Anju Thomas

anjuandsunil@yahoo.co.in9605481085

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026